Axiom Exhibiting at Outsourcing in Clinical Trials New England 2022
TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services...
Day: October 12, 2022
Loos, France, Isovital Headquarter, Oct 12th 2022 – Radiopharma Logistics Group (RLG); ISOTOPES SERVICES INTERNATIONAL (ISI). NEW SHAREHOLDER
Loos, France, Isovital Headquarter, Oct 12th 2022 - Radiopharma Logistics Group (RLG); ISOTOPES SERVICES INTERNATIONAL (ISI). NEW SHAREHOLDERClaude Poliart, founder and manager...
Codex DNA Announces Plan to Change Corporate Name to Telesis Bio
Novel name reflects expansion of capabilities and solutionsSAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY),...
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
TEL AVIV, Israel, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on...
BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
Sientra Announces Preliminary Unaudited Third Quarter Financial Results and Signing of Senior Secured Loan Facilities With Deerfield Management
Anticipates total third quarter net sales of $21.5-$22.5 million, up 10-15% compared to the prior year period Restructured balance sheet...
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions
Company expects to commence patient enrollment and dosing in Q1 2023OCALA, Fla, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
Junshi Biosciences and Coherus Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology
Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients...
T2 Biosystems Announces Preliminary Third Quarter 2022 Financial Results and Updates 2022 Financial Outlook
LEXINGTON, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of...
Albireo to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid...
T2 Biosystems Announces Reverse Stock Split Effective Today
TTOO common stock expected to begin trading on a split-adjusted basis on October 13, 2022LEXINGTON, Mass., Oct. 12, 2022 (GLOBE...
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022
Six abstracts selected for presentation, including three oral presentationsWALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc.,...
Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting
- Three late-breaking presentations to feature emerging evidence of VRDN-001 efficacy and differentiation - - VRDN-001 10mg/kg proof of concept...
Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer
CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today...
Pasithea Therapeutics Acquires AlloMek Therapeutics
-- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application...
Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs
Accomplished industry leader with over twenty years of experience building lasting relationships with global regulatory agencies and guidance in the...
Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium
Initial Phase 1/1b patient data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors show safe and...
MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022
ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused...
Synthetic Biologics Rebrands as Theriva Biologics
Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administrationROCKVILLE, Md., Oct. 12, 2022...